Clinical analysis of prophylactic lamivudine reduced hepatitis B virus reactivation in patients with B-cell non-Hodgkin's lymphoma receiving rituximab combination chemotherapy

Journal of Leukemia and Lymphoma

Volumn 21, Issue 9, 2012, Pages 524-527

  Zhu, Jian Yi ^a   Chen, Fang Yuan ^a   Xiao, Fei ^a   Huang, Hong Hui ^a   Zhong, Hua ^a   Han, Xiao Feng ^a   Wang, Tin ^a   Xu, Lan ^a   Zhong, Lu ^a   Ni, Bei Wen ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

B cell; Hepatitis B virus; Lamivudine; Lymphoma; Reactivation; Rituximab

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; RITUXIMAB; VIRUS DNA;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; HEPATITIS B; HUMAN; INCIDENCE; LARGE CELL LYMPHOMA; LIVER FUNCTION; LIVER INJURY; PREVALENCE; PROPHYLAXIS; RETROSPECTIVE STUDY; VIRUS REACTIVATION;

EID: 84874968872     PISSN: 10099921     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.l009-9921.2012.09.004     Document Type: Article

References (23)

1. Chnise source
2. Park SC, Jeong SH, Kim J, et al. High prevalence of hepatitis B virus infection in patients with B-cell non-Hodgkin's lymphoma in Korea. J Med Virol, 2008, 80: 960-966.
3. Chen MH, Hsiao LT, Chiou TJ, et al. High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin's lymphoma. Ann Hematol, 2008, 87: 475-480.
4. Wang F, Xu RH, Han B, et al. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer, 2007, 109: 1360-1364.
5. Marcucci F, Mele A, Spada E, et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica, 2006, 91: 554-557.
6. Mendez-Navarro J, Corey KE, Zheng H, et al. Hepatitis B screening, prophylaxis and reactivation in the era of rituximab-based chemotherapy. Liver Int, 2011, 31: 330-339.
7. Koo YX, Tan DS, Tan BH, et al. Risk of hepatitis B virus reactivation in patients who are hepatitis B surface antigen negative/antibody to hepatitis B core antigen positive and the role of routine antiviral prophylaxi. J Clin Oncol, 2009, 27: 2570-2571.
8. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol, 2000, 62: 209.
9. Chnise source
10. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med, 2001, 344: 68-69.
11. Domingo-Domenech E, Gonzlez-Barca E, Estany C, et al. Combined treatment with anti-CD, (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas. Haematologica, 2002, 87: 1229-1230.
12. Westhoff TH, Jochimsen F, Schmittel A, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood, 2003, 102: 1930.
13. Ozgonenel B, Moonka D, Savasan S. Fulminant hepatitis B following rituximab therapy in a patient with Evans syndrome and large B=cell lymphoma. Am J Hematol, 2006, 81: 302.
14. Tsutsumi Y, Kanamori H, Mori A, et al. Reactivation of hepatitis B virus with rituximab. Exp Opin. Drag Saf, 2005, 4: 599-608.
15. Yeo W, Chan PKS, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol, 2004, 22: 927-934.
16. Lee GW, Ryu MH, Lee JL, et al. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis B surface antigen-positive patients with non-Hodgkin's lymphoma who receive cytotoxic chemotherapy. J Korean Med Sci, 2003, 18: 849-854.
17. Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology, 2008, 47: 844-853.
18. Kim JS, Hahn JS, Park SY, et al. Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma. Yonsei Med J, 2007, 48: 78-89.
19. Dai MS, Chao TY, Kao WY, et al. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol, 2004, 83: 769-774.
20. Hamaki T, Kami M, Kusumi E, et al. Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab. Am J Hematol, 2001, 68: 292-294.
21. Pei SN, Chen CH, Lee CM, et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol, 2010, 89: 255-262.
22. Fam Y, Luo C, Luo L, et al. Retrospective analysis of hepatitis B virus reactivation after rituximab combination chemotherapy in patients with B-cell lymphoma. Chin-Germ J Oncol, 2011, 10: 721-725.
23. Yeo W, Chan TC, Leung N, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol, 2009, 27: 605-611.